BlossomHill Therapeutics prices $150M IPO at $16 per share
BlossomHill Therapeutics priced its IPO at $16.00 per share, selling 9,375,000 shares to raise about $150.0 million in gross proceeds, according to the company’s Aug. 6, 2026 press release. The offering was upsized and includes a 30-day option for 1,406,250 more shares. Shares are set to trade on Nasdaq as BLSM on Aug. 7, 2026.
How this was made
The 30-second read
Why it matters
The key tradable event is the IPO pricing and scheduled Nasdaq start, which affects near-term order flow, volatility, and risk for any IPO-focused strategy.
Market read
This is a primary capital-markets disclosure: IPO size, price, and debut timing for BLSM.
What to watch
No details are provided on lockups, investor allocation, or valuation vs peers, which are key drivers of first-day trading and post-IPO drift.
Background
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing small molecule cancer treatments, with lead programs BH-30643 (EGFR inhibitor) and BH-30236 (CLK inhibitor).
Ticker impact
BlossomHill Therapeutics priced its IPO at $16 and set a Nasdaq debut under ticker BLSM, with $150M gross proceeds and an over-allotment option.
Likely elevated first-day volatility around the Aug. 7 Nasdaq start, with direction dependent on demand versus the $16 offer price.
The article discloses offer size, price, and listing timing, which are actionable for positioning around the debut, but it provides no new clinical or financial performance data.
Market effects
Adds a new clinical-stage small-molecule oncology IPO to the biotech pipeline, which can marginally affect sentiment toward early-stage financings.
Primarily US-focused listing and capital raise; limited spillover beyond Nasdaq biotech flows.
Low global relevance given the article is US IPO mechanics rather than international regulatory or trial outcomes.
Counterpoint
IPO pricing at $16 does not guarantee post-listing performance; demand could be weaker than implied, leading to early selling pressure.
Key entities
- companyBlossomHill Therapeutics, Inc.
Clinical-stage biopharmaceutical company that priced its IPO at $16 per share and plans Nasdaq trading under BLSM.
- venueNasdaq Global Select Market
Planned listing venue for the IPO shares beginning Aug. 7, 2026.
- financial_advisorsJ.P. Morgan, Leerink Partners, Guggenheim Securities
Lead book-running managers for the IPO.
